Patents by Inventor Bianka Prinz

Bianka Prinz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY OF CANCER INVOLVING MULTI-SPECIFIC BINDING PROTEINS THAT BIND NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
    Publication number: 20230303702
    Abstract: Combination therapy of a cancer with a multi-specific binding protein that bind a tumor associated antigen, the NKG2D receptor, and CD16, in combination with a second anti-cancer agent are described. Also described are pharmaceutical compositions of the multi-specific binding protein, and therapeutic methods useful for the treatment of cancer in combination with a second anti-cancer agent.
    Type: Application
    Filed: January 4, 2023
    Publication date: September 28, 2023
    Inventors: Gregory P. Chang, Ann F. Cheung, Asya Grinberg, Eva Gutierrez, William Haney, Bradley M. Lunde, Nicolai Wagtmann, Bianka Prinz
  • ANTI-COAGULATION FACTOR XI ANTIBODIES
    Publication number: 20230287141
    Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
    Type: Application
    Filed: April 18, 2023
    Publication date: September 14, 2023
    Applicants: Merck Sharp & Dohme LLC, Adimab, LLC
    Inventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz, Vaishnavi Ganti, Mohammad Tabrizifard
  • MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE AND METHODS OF USE THEREOF
    Publication number: 20230265197
    Abstract: This invention provides fully human monoclonal antibodies that recognize HER2. The invention further provides methods of using such monoclonal antibodies in a variety of therapeutic, diagnostic, and prophylactic indications.
    Type: Application
    Filed: October 26, 2022
    Publication date: August 24, 2023
    Inventors: Natalya D. BODYAK, Michael J. DEVIT, Eric M. KRAULAND, Timothy B. LOWINGER, Peter U. PARK, Bianka PRINZ, Aleksandr V. YURKOVETSKIY
  • COMBINATION THERAPY OF CANCER INVOLVING MULTI-SPECIFIC BINDING PROTEINS THAT BIND NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
    Publication number: 20230227562
    Abstract: Combination therapy of a cancer with a multi-specific binding protein that bind a tumor associated antigen, the NKG2D receptor, and CD16, in combination with a second anti-cancer agent are described. Also described are pharmaceutical compositions of the multi-specific binding protein, and therapeutic methods useful for the treatment of cancer in combination with a second anti-cancer agent.
    Type: Application
    Filed: January 4, 2023
    Publication date: July 20, 2023
    Inventors: Gregory P. Chang, Ann F. Cheung, Asya Grinberg, Eva Gutierrez, William Haney, Nicolai Wagtmann, Bradley M. Lunde, Bianka Prinz
  • Anti-CD25 for tumour specific cell depletion
    Patent number: 11697688
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-674 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: QCVQGYRA and RWTQPQLICTG on CD25 Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: July 11, 2023
    Assignees: Tusk Therapeutics Ltd., Cancer Research Technology Limited
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, James Geoghegan, Bianka Prinz, Sergio Quezada
  • HUMAN PD-L2 ANTIBODIES AND METHODS OF USE THEREFOR
    Publication number: 20230174661
    Abstract: The present disclosure is directed to antibodies binding to PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L2.
    Type: Application
    Filed: March 15, 2019
    Publication date: June 8, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventors: Michael A. CURRAN, Ashvin R. JAISWAL, Dongxing ZHA, Kui VOO, Carlo TONIATTI, Bianka PRINZ, Nadthakarn BOLAND
  • Anti-coagulation factor XI antibodies
    Patent number: 11661460
    Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: May 30, 2023
    Assignees: Merck Sharp & Dohme LLC, Adimab, LLC
    Inventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Vaishnavi Ganti, Mohammad Tabrizifard, Bianka Prinz
  • Anti-CD39 antibody compositions and methods
    Patent number: 11655303
    Abstract: The invention provides anti-CD39 antibody compositions and their use in treating cancer.
    Type: Grant
    Filed: September 15, 2020
    Date of Patent: May 23, 2023
    Assignee: Surface Oncology, Inc.
    Inventors: Scott Chappel, Andrew Lake, Michael Warren, Austin Dulak, Erik Devereaux, Pamela M. Holland, Tauqeer Zaidi, Matthew Rausch, Bianka Prinz, Nels P. Nielson, Sonia Das, Alison M. O'Neill
  • Anti-TIGIT Antibodies
    Publication number: 20230134375
    Abstract: Isolated antibodies or antigen-binding portions that bind to human TIGIT (T-cell immunoreceptor with Ig and ITIM domains) are provided. In some embodiments, the antibody or antigen-binding portion thereof has a binding affinity (KD) for human TIGIT of less than 5 nM. In some embodiments, the anti-TIGIT antibody blocks binding of CD155 and/or CD112 to TIGIT.
    Type: Application
    Filed: June 29, 2022
    Publication date: May 4, 2023
    Applicant: Seagen Inc.
    Inventors: Julia C. Piasecki, Courtney Beers, Scott Peterson, Bianka Prinz
  • CD38 MODULATING ANTIBODY AGENTS
    Publication number: 20230103584
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.
    Type: Application
    Filed: June 8, 2018
    Publication date: April 6, 2023
    Inventors: Pascal Merchiers, Anne Goubier, Kevin Moulder, Nina Eissler, Josephine Salimu, Simone Filosto, Beatriz Goyenechea Corzo, Hemanta Baruah, Bianka Prinz
  • CD38 MODULATING ANTIBODY
    Publication number: 20230089373
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.
    Type: Application
    Filed: November 30, 2022
    Publication date: March 23, 2023
    Inventors: Anne GOUBIER, Josephine SALIMU, Kevin MOULDER, Beatriz GOYENECHEA CORZO, Simone FILOSTO, Pascal MERCHIERS, Nina EISSLER, Hemanta BARUAH, Bianka PRINZ
  • Anti-TIGIT Antibodies
    Publication number: 20230050440
    Abstract: Isolated antibodies that bind to human TIGIT (T-cell immunoreceptor with Ig and ITIM domains) are provided. In some embodiments, the antibody has a binding affinity (KD) for human TIGIT of less than 5 nM. In some embodiments, the anti-TIGIT antibody blocks binding of CD155 and/or CD112 to TIGIT. In some embodiments, the antibodies are afucosylated.
    Type: Application
    Filed: June 10, 2022
    Publication date: February 16, 2023
    Applicant: Seagen Inc.
    Inventors: Julia C. Piasecki, Courtney Beers, Scott Peterson, Bianka Prinz, Shyra Gardai
  • ANTI-IL-27 ANTIBODIES AND USES THEREOF
    Publication number: 20230042258
    Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.
    Type: Application
    Filed: April 6, 2022
    Publication date: February 9, 2023
    Applicants: Surface Oncology, Inc., Adimab LLC
    Inventors: Jonathan HILL, Scott CHAPPEL, Michael GLADSTONE, Bianka PRINZ, Andrew LAKE, Christine MILLER, Kerry WHITE, Jing HUA, Pamela M. HOLLAND, Matthew RAUSCH, Devapregasan MOODLEY
  • ANTIBODY MOLECULES TO CD73 AND USES THEREOF
    Publication number: 20230039109
    Abstract: Antibody molecules that bind to CD73 are disclosed. The anti-CD73 antibody molecules can be used to treat, prevent and/or diagnose cancer.
    Type: Application
    Filed: March 15, 2022
    Publication date: February 9, 2023
    Inventors: Bianka Prinz, Jerry M. Thomas, Ansgar Brock, Viviana Cremasco, Catherine Anne Sabatos-Peyton, Glenn Dranoff, Scott Chappel, Andrew Lake, Alison Paterson, Rachel W. O'Connor, Michael Warren, Pamela Holland, Kulandayan Kasi Subramanian, Helena Marie-Louise Fjaellskog, Dirksen Bussiere, Mikias Woldegiorgis, Wei Shu, John Delmas Venable, III, Michael Gladstone, Jonathan Hill, Christine Miller
  • ANTI-CD19 ANTIBODIES AND MULTI-SPECIFIC BINDING PROTEINS
    Publication number: 20230037815
    Abstract: Provided herein are anti-CD 19 antibodies and multi-specific binding proteins that bind CD 19, CD3, and serum albumin. Also provided are pharmaceutical compositions comprising these antibodies or multi-specific binding proteins, expression vectors and host cells for making these antibodies or multi-specific binding proteins, and methods of use of these antibodies or multi-specific binding proteins in treating cancers.
    Type: Application
    Filed: December 11, 2020
    Publication date: February 9, 2023
    Inventors: Patrick A. Baeuerle, Jennifer Michaelson, Bochong Li, Naveen Mehta, Jonathan Belk, Nathan Sharkey, Bianka Prinz, Bradley M. Lunde, Nga Rewa Houston
  • ANTI-SERUM ALBUMIN ANTIBODIES
    Publication number: 20230032087
    Abstract: The invention relates to anti-serum albumin antibodies and multi-specific binding proteins comprising the same. The invention also relates to pharmaceutical compositions comprising the antibodies or multi-specific binding proteins, expression vectors and host cells for making the antibodies or multi-specific binding proteins, and methods of use of the antibodies or multi-specific binding proteins in treatment of diseases or disorders.
    Type: Application
    Filed: December 11, 2020
    Publication date: February 2, 2023
    Inventors: Patrick A. Baeuerle, Jennifer Michaelson, Bochong Li, Naveen Mehta, Bianka Prinz, Bradley M. Lunde, Nga Rewa Houston
  • CD38 modulating antibody
    Patent number: 11542338
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: January 3, 2023
    Assignee: BLACK BELT THERAPEUTICS LIMITED
    Inventors: Anne Goubier, Josephine Salimu, Kevin Moulder, Beatriz Goyenechea Corzo, Simone Filosto, Pascal Merchiers, Nina Eissler, Hemanta Baruah, Bianka Prinz
  • Human PD-L1 antibodies and methods of use therefor
    Patent number: 11525002
    Abstract: The present disclosure is directed to antibodies binding to PD-L1 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: December 13, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Michael A. Curran, Carlo Toniatti, Ashvin R. Jaiswal, Dongxing Zha, Kui Voo, Bianka Prinz, Nadthakarn Boland
  • Monoclonal antibodies against HER2 epitope and methods of use thereof
    Patent number: 11518812
    Abstract: This invention provides fully human monoclonal antibodies that recognize HER2. The invention further provides methods of using such monoclonal antibodies in a variety of therapeutic, diagnostic, and prophylactic indications.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: December 6, 2022
    Assignee: Mersana Therapeutics, Inc.
    Inventors: Natalya D. Bodyak, Michael J. DeVit, Eric M. Krauland, Timothy B. Lowinger, Peter U. Park, Bianka Prinz, Aleksandr V. Yurkovetskiy
  • ENGINEERED PH-DEPENDENT ANTI-CD3 ANTIBODIES, AND METHODS FOR THEIR GENERATION AND USE
    Publication number: 20220380463
    Abstract: Engineered pH-dependent anti-CD3 binding domains and antibodies and/or antigen-binding domains comprising same, including multispecific antibodies, with, inter alia, desirable T-cell activation and (re)directed target cell killing potency and developability, profiles are provided, as well as methods for their identification, isolation, and generation, and methods for their preparation and use.
    Type: Application
    Filed: June 8, 2020
    Publication date: December 1, 2022
    Inventors: James GEOGHEGAN, Bianka PRINZ, Robert PEJCHAL